A selective cyclo-oxygenase-2 inhibitor, NS-398, may improve portal hypertension without inducing gastric mucosal injury

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue 7, 1999, Pages 642-651

  Tsugawa, Kouji ^a   Hashizume, Makoto ^a   Migou, Shinichirou ^a   Kishihara, Fumiaki ^a   Kawanaka, Hirofumi ^a   Tomikawa, Morimasa ^a   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cyclo oxygenase 2; Portal hypertensive gastropathy; Prostaglandin

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ALCOHOL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTACYCLIN; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; INTESTINE BLOOD FLOW; LIVER CIRCULATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN INDUCTION; RAT; STOMACH INJURY; STOMACH MUCOSA; VEIN LIGATION;

EID: 0032777750     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01930.x     Document Type: Article

References (43)

1. 1 Genecin P, Groszmann RJ. Portal hypertension. In: Schiff L (ed.). Diseases of the Liver, 7th edn. Philadelphia: JB Lippincott, 1993; 935-73.
2. 2 Genecin P, Groszmann RJ. Biology of portal hypertension. In: Arias T, Boyer JL, Fausto N et al. (eds). The Liver: Biology and Pathophysiology. New York: Raven Press, 1994; 1327-42.
3. 3 Vorobioff J, Bredfeldt JE, Groszmann RJ et al. Hyperdynamic circulation in portal-hypertensive rat model: A primary factor maintenance of chronic portal hypertension. Am. J. Physiol. 1983; 244: G52.
4. 4 Sikuler E, Groszmann RJ. Hemodynamic studies in long and short term portal hypertensive rats: The relation to systemic glucagon levels. Hepatology 1988; 6: 414-18.
5. 5 Sitzmann JV, Bulkley GB, Mitchell MC et al. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann. Surg. 1989; 209: 322-7.
6. 6 Sitzmann JV, Li SS, Adkinson NF et al. Evidence for role of prostacyclin as a systemic hormone in portal hypertension. Surgery 1991; 109: 149-53.
7. 7 Hashizume M, Inokuchi K, Tanaka K. The role of prostacyclin in patients with portal hypertension. Liver 1985; 5: 89-93.
8. 8 Ferraz JGP, Wallace JL. Prostaglandin modulates the responsiveness of the gastric microcirculation to sodium nitroprusside in cirrhotic rats. Hepatology 1996; 23: 123-9.
9. 9 Fernández M, Garcia-Pagán JC, Casadevall M et al. Acute and chronic cyclooxygenase blockade in portal-hypertensive rats: Influence on nitric oxide biosynthesis. Gastroenterology 1996; 110: 1529-35.
10. 10 Xie W, Chipman JG, Robertson DL et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA 1991; 88: 2692-6.
11. 11 Kujubu DA, Fletcher BS, Varnum BC et al. TIS10, a pholbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase. J. Biol. Chem. 1991; 266: 12866-72.
12. 12 Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol. 1996; 25 (Suppl. 102): 9-21.
13. 13 Futaki N, Takahashi S, Yokoyama M et al. NS-398, a new anti-inflammatory agent, selectivity inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47: 55-9.
14. 14 Futaki N, Yoshikawa K, Hamasaki Y et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol. 1993; 24: 105-10.
15. 15 Futaki N, Arai I, Hamasaki Y et al. Selective inhibition of NS-398 on prostanoid production in inflamed tissues in rat carrageenan-air-pouch inflammation. J. Pharm. Pharmacol. 1993; 45: 753-5.
16. 16 Arai I, Hamasaki Y, Futaki N et al. Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. Res. Commun. Chem. Pathol. Pharmacol. 1993; 81: 259-70.
17. 17 Trevino HH, Brady III CE, Schenker S. Portal hypertensive gastropathy. Dig. Dis. 1996; 14: 258-70.
18. 18 El Newihi HM, Kanji VK, Mihas AA. Activity of gastric mucosal nitric oxide synthase in portal hypertensive gastropathy. Am. J. Gastroenterol. 1996; 91: 535-8.
19. 19 Tanoue K, Tarnawski AS, Kishihara F et al. Effect of teprenone on portal hypertensive gastric mucosa. Digestion 1996; 57: 35-40.
20. 20 Casadevall M, Pique JM, Cirera I et al. Increased blood hemoglobin attenuates splanchnic vasodilatation in portal-hypertensive rats by nitric oxide inactivation. Gastroenterology 1996; 110: 1156-65.
21. 21 Hashizume M, Tanaka K, Inokuchi K. Morphology of gastric microcirculation in cirrhosis. Hepatology 1983; 3: 1008-12.
22. 22 Vallence P, Moncade S. Hyperdynamic circulation in cirrhosis: A role for nitric oxide? Lancet 1991; 377: 776-8.
23. 23 Tarnawski AS, Sarfeh IJ, Stachura J et al. Microvascular abnormalities of the portal hypertensive gastric mucosa. Hepatology 1988; 8: 1288-494.
24. 24 Tanoue K, Kitano S, Hashizume M et al. A rat model of esophageal varices. Hepatology 1991; 13: 353-8.
25. 25 Robert A, Nezamis JE, Lancaster C et al. Cytoprotection by prostaglandins in rats: Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 1979; 77: 433-43.
26. 2 or sodium thiosulfate. Gastroenterology 1986; 91: 1415-26.
27. 27 McCormack TT, Sims J, Eyre-Brook I et al. Gastric lesions in portal hypertension: Inflammatory gastritis or congestive gastropathy? Gut 1985; 26: 1226-32.
28. 28 D'Amico G, Montalbano L, Traina M et al. Natural history of congestive gastropathy in cirrhosis. Gastroenterology 1990; 99: 1558-64.
29. 29 Quintero E, Pique JM, Bombi JA et al. Gastric mucosal vascular ectasia causing bleeding in cirrhosis: A distinct entity associated with hypergastrinaemia and low levels of pepsinogen I. Gastroenterology 1987; 93: 1054-61.
30. 30 Iseki S. Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach. Histochem. J. 1995; 25: 323-8.
31. 31 Kargman S, Charleson S, Cartwright M et al. Characterization of prostaglandin G/H synthase 1 and 2 in rats, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111: 445-54.
32. 32 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl Acad. Sci. USA 1975; 72: 2994-8.
33. 2 from prostaglandin endoperoxides. Nature 1976; 261: 558-60.
34. 34 Morley J, Bray MA, Jones RW et al. Prostaglandin and thromboxane production by human and guinea-pig macrophages and leucocytes. Prostaglandins 1979; 17: 730-6.
35. 35 Panes J, Bordas JM, Pique JM et al. Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology 1992; 103; 1875-82.
36. 36 Ohta M, Hashizume M, Higashi H et al. Portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy. Hepatology 1994; 20: 1432-6.
37. 37 Kotzampassi K, Eleftheriadis E, Aletras H. Gastric mucosal blood flow in portal hypertension patients: A laser Doppler flowmetry study. Hepatogastroenterology 1992; 39: 39-42.
38. 38 Guslandi M, Sorghi M, Foppa L et al. Congestive gastropathy versus chronic gastritis: A comparison of some pathophysiological aspects. Digestion 1993; 54: 160-2.
39. 39 Iwao T, Toyonaga A, Ikegami M et al. Reduced gastric mucosal blood flow in patients with portal-hypertensive gastropathy. Hepatology 1993; 18: 36-40.
40. 40 Lamarque D, Levoir D, Duvoux C et al. Measurement of gastric intramucosal pH in patients with cirrhosis and portal hypertensive gastropathy. Gastroenterol. Clin. Biol. 1994; 18: 969-74.
41. 41 Geraghty JG, Angerson WJ, Carter DC. A study of regional gastric mucosal blood flow in a rat model of hepatic cirrhosis. Am. J. Physiol. 1992; 262: G727-31.
42. 42 Sarfeh IJ, Tarnawski A, Malki A. Portal hypertension and gastric mucosal injury in rats. Gastroenterology 1983; 34: 987-93.
43. 43 Morita I et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem. 1995; 270: 24019-23.